People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Reunion Neuroscience, Inc. | — | Pharmaceuticals | Series D+ | $119.8M | $1.5B | 2024 |
| Aulos Bioscience, Inc. | — | Biotechnology | Series A | $20.0M | $41.1M | 2020 |
| Replicate Bioscience, Inc. | — | Biotechnology | Series B | $20.0M | $614.8M | 2021 |
| Deep Apple Therapeutics, Inc. | — | Biotechnology | Series A | $5.0M | $90.7M | 2021 |
| Nine Square Therapeutics Corp | — | Biotechnology | Series A | $4.2M | $151.8M | 2020 |
| Initial Therapeutics, Inc. | — | Biotechnology | Seed | $3.8M | $168.6M | 2020 |
Michael Ehlers at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Ehlers on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Harrison | 5 | 19 |
| Spiros Liras | 3 | 6 |
| Joseph Yanchik | 2 | 3 |
| Briggs Morrison | 1 | 8 |
| Ansbert Gadicke | 1 | 7 |
| Alon Lazarus | 1 | 7 |
| MATTHEW JACOBSON | 1 | 6 |
| Robert Alexander | 1 | 6 |
| Gregory Mayes | 1 | 5 |
| Edward Smith | 1 | 5 |
| Nathan Bryson | 1 | 3 |
| Yechezkel Barenholz | 1 | 3 |
| Mark Theeuwes | 1 | 3 |
| Paul Da Silva Jardine | 1 | 3 |
| Anna Batarina | 1 | 2 |
| Rajesh Chopra | 1 | 2 |
| Brian Shoichet | 1 | 2 |
| Ellen Lubman | 1 | 2 |
| Yanay Ofran | 1 | 2 |
| Natalie Sacks | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.